Continued Access to RXDX-105

Summary

This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.

Timeline

Start

2018-12-14

Primary completion

2020-09-30

Completion

2020-09-30

Drugs

Indications